Survey of human-use adjuvants

References

• Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants — a balance between toxicity and adjuvanticity. Vaccinell(3), 293–306 (1993).
   Google Scholar
• Ramon G. Sur l'augmentation anormale del'antitoxine chez les chevaux producteurs de serum antidiphthérique. Bull Soc. CentE Merl Vet. 101,227–234 (1925).
   Google Scholar
• Chedid L. Adjuvants of immunity Ann. Inst. Pasteur Immunol 136D(3), 283–291 (1985).
   PubMedGoogle Scholar
• Gregoriadis G, Allison AC, Poste G. Immunological Adjuvants and Vaccines. Plenum Press, NY, USA (1989).
   Google Scholar
• Edelman R, Tacket CO. Adjuvants. Int. Rev Immunol 7(1), 51–66 (1990).
   PubMedGoogle Scholar
• Allison AC, Byars NE. Adjuvants for a new generation of vaccines. In: New Generation Vaccines. Woodrow GC, Levine MM (Eds). Marcel Dekker, NY, USA, 129–140 (1990).
   Google Scholar
• Spriggs DR, Koff WC. Topics in Vaccine Adjuvant Research. CRC Press, Boca Raton, FL, USA (1991).
   Google Scholar
• Edelman R. An update on vaccine adjuvants in clinical trial. AIDS Res. Hum. Retroviruses 8 (8), 1409–1411 (1992).
   Google Scholar
• Alving CR, Glass M, Detrick B. Summary: Adjuvants/Clinical Trials Working Group. AIDS Res. Hum. Retroviruses 8(8), 1427–1430 (1992).
   Google Scholar
• Audibert FM, Lise LD. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today14(6), 281–284 (1993).
   PubMedGoogle Scholar
• Myers KR, Gustafson GL. Adjuvants for human vaccine usage: a rational design. In: Vaccine and Immunotherapy Cryz SJ Jr (Ed.). Pergamon Press, NY, USA 404–411 (1991).
   Google Scholar
• Hui GS. Liposomes, muramyl dipeptide derivatives and nontoxic lipid A derivatives as adjuvants for human malaria vaccines. Am Bop. Med. 4g. 50(4 Suppl), 41–51 (1994).
   Google Scholar
• Rabinovich NR, McInnes P, Klein DL, Hall BE Vaccine technologies: view to the future. Science 265(5177), 1401–1404 (1994).
   PubMed Web of Science ®Google Scholar
• Cooper PD. The selective induction of different immune responses by vaccine adjuvants. In: Strategies in Vaccine Design Ada GL (Ed.). Landes, TX, USA, 125–158 (1994).
   Google Scholar
• Stewart-Tull DE. The Theory and Practical Application of Adjuvants. Wiley, Chichester, England (1994).
   Google Scholar
• Powell NE, Newman MJ. Vaccine Design: the Subunit and Adjuvant Approach. Plenum Press, NY, USA (1995).
   Google Scholar
• Gupta RK, Siber GR. Adjuvants for human vaccines — current status, problems and future prospects. Vaccine 13(14), 1263–1276 (1995).
   PubMed Web of Science ®Google Scholar
• Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol 17(11), 1075–1081 (1999).
   PubMed Web of Science ®Google Scholar
• O'Hagan DT (Ed.). Vaccine Adjuvants. Preparation Methods and Research Protocols, Humana Press, NJ, USA (2000).
   Google Scholar
• Hunter RL. Overview of vaccine adjuvants: present and future. Vaccine 20, S7—S12 (2002).
   Web of Science ®Google Scholar
• Kenney RT, Rabinovich NR, Pichyangkul S, Price VL, Engers HD. Second meeting on novel adjuvants currently in/close to human clinical testing. Vaccine 20,2155–2163 (2002).
   Google Scholar
• Edelman R. The development and use of vaccine adjuvants. Mal Biotechnol 21(2), 129–148 (2002).
   PubMed Web of Science ®Google Scholar
• Douglas RG Jr. The children's vaccine initiative — will it work? J. Infect. Dis. 168, 269–274 (1993).
   Web of Science ®Google Scholar
• Wittet S. Introducing GAVI and the Global Fund for Children's Vaccines. Vaccine 19, 385–386 (2000).
   PubMed Web of Science ®Google Scholar
• McElrath MJ, Corey L, Montefiori D et al. A Phase II study of two HIV Type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV Type 1 infection. AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 16(9), 907–919 (2000).
   Google Scholar
• Xiao L, Rafi-Janajreh A, Patterson P, Zhou Z, Lal AA. Adjuvants and malaria vaccine development. Chem. Immunol 80, 343–365 (2002).
   PubMedGoogle Scholar
• Ramon G. Procédés pour accroitre la production des antitoxines. Ann. Inst. Pasteur 40, 1–10 (1926).
   Google Scholar
• Vogel FR, Powell ME, Alving CR. A compendium of vaccine adjuvants and excipients. NIH/NIAID/DMID, (2001) www.niaid.nih.gov/aidsvaccine/pdf/ compendium.pdf.
   Google Scholar
• Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal and gene-gun inoculations. Proc. Natl Acad. Li. USA 90(24), 11478–11482 (1993).
   Google Scholar
• Hoffman SL, Edelman R, Bryan JP etal. Safety, immunogenicity and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria and squalane as adjuvant. Am J. Trop. Med Hyg. 51(5), 603–612 (1994).
   Google Scholar
• Fries LF, Gordon DM, Richards RL etal Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Nat! Acad. Sci. USA 89(1), 358–362 (1992).
   Google Scholar
• Lidgate DM, Byars NE. Development of an emulsion-based muramyl dipeptide adjuvant formulation for vaccines. In: Vaccine Design: the Subunit and Adjuvant Approach. Powell MF, Newman MJ (Eds). Plenum Press, NY, USA, 313–324 (1995).
   Google Scholar
• Wintsch J, Chaignat CL, Braun DG etal Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. .1. Infect. Dis. 163(2), 219–225 (1991).
   Google Scholar
• Schijns VE. Immunological concepts of vaccine adjuvant activity. Cun: Opin. Immunal 12(4), 456–463 (2000).
   Google Scholar
• Schijns VE. Activation and programming of adaptive immune responses by vaccine adjuvants. Veterinary Sciences Tomorrow 3, August 2001, (2001). www.vetscite.org.
   Google Scholar
• Grakoui A, Bromley SK, Sumen C et al The immunological synapse: a molecular machine controlling T-cell activation.Science 285(5425), 221–227 (1999).
   PubMed Web of Science ®Google Scholar
• Schijns VE. Antigen delivery systems and immunostimulation. Vet. Immunal Immunopathol 87(3-4), 195–198 (2002).
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunal Today 13(1), 11–16 (1992).
   PubMedGoogle Scholar
• Janeway CA Jr, Medzhitov R. Innate immune recognition. Ann. Rev. Immunal 20,197–216 (2002).
   PubMed Web of Science ®Google Scholar
• Matzinger P The danger model: a renewed sense of self. Science 296(5566), 301–305 (2002).
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunal Rev. 156,199–209 (1997).
   PubMed Web of Science ®Google Scholar
• Glenny AT, Buttle GAH, Stevens ME Rate of disappearance of diphtheria toxoid injected into rabbits and guinea-pigs: toxoid precipitated with alum. Pathol Bacterial 34,267–275 (1931).
   Google Scholar
• Szakal AK, Tew JG. Follicular dendritic cells: B-cell proliferation and maturation. Cancer Res. 52 (Suppl. 19), 5554s-5556s (1992).
   Google Scholar
• Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 272(5258), 50–53 (1996).
   PubMed Web of Science ®Google Scholar
• Yamanaka M, Hiramatsu K, Hirahara T et al Pathological studies on local tissue reactions in guinea-pigs and rats caused by four different adjuvants. j Vet. Med. Sci. 54(4), 685–692 (1992).
   Google Scholar
• Rothel JS, Corner LA, Lightowlers MW et al Antibody and cytokine responses in efferent lymph following vaccination with different adjuvants. Vet. Immunal Immunopathol 63(1-2), 167–183 (1998).
   PubMed Web of Science ®Google Scholar
• Langenkamp A, Messi M, Lanzavecchia A, Sallusto E Kinetics of dendritic cell activation: impact on priming of Thl, Th2 and nonpolarized T-cells. Nat. Immunal 1(4), 311–316 (2000).
   Google Scholar
• Newman MJ, Powell ME Immunological and formulation design considerations for subunit vaccines. In: Vaccine Design: the Subunit and Adjuvant Approach. Powell ME, Newman MJ (Eds).Plenum Press, NY, USA, 1–42 (1995).
   Google Scholar
• HogenEsch H. Mechanisms of stimulation of the immune response by aluminumadjuvants. Vaccine 20, S34—S39 (2002).
   Web of Science ®Google Scholar
• Newman MJ, Wu JY, Gardner BH et al Saponin adjuvant induction of ovalbumin-specific CD8* cytotoxic T-lymphocyte responses. j Immunal 148(8), 2357–2362 (1992).
   Google Scholar
• Newman MJ, Wu JY, Gardner BH et al. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine 15(9), 1001–1007 (1997).
   Google Scholar
• Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA. The common vaccine adjuvant aluminum hydroxide upregulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. 'minim. 69(2), 1151–1159 (2001).
   Google Scholar
• Yip HC, Karulin AY, Tary-Lehmann M etal Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. Immunal 162(7), 3942–3949 (1999).
   Google Scholar
• Gupta RK, Siber GR. Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. Biologicals 22(1), 53–63 (1994).
   PubMed Web of Science ®Google Scholar
• Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant: past experiences and new directions. In: Vaccine Design: the Subunit and Adjuvant Approach. Powell ME, Newman MJ (Eds). Plenum Press, NY, USA, 495–524 (1995).
   Google Scholar
• Kensil C, Wu JY, Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. In: Vaccine Design: the Subunit and Adjuvant Approach. Powell ME, Newman MJ (Eds). Plenum Press, New York, NY, USA, 525–542. (1995).
   Google Scholar
• Hui GS, Chang SP, Gibson H etal Influence of adjuvants on the antibody specificity to the Plasmodium falciparvm major merozoite surface protein, gp195. Immunal 147(11), 3935–3941 (1991).
   Google Scholar
• Kenney JS, Hughes BW, Masada MP, Allison AC. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. Immunal Methods 121(2), 157–166 (1989).
   PubMed Web of Science ®Google Scholar
• Hunter RL, Lal AA. Co-polymer adjuvants in malaria vaccine development. Am. Trap. Med. Hyg: 50(4 Suppl), 52–58 (1994).
   Google Scholar
• Siegrist CA, Pihlgren M, Tougne C etal In: 5th Annual Conference on Vaccine Research. (2002) (Abstract #S37).
   Google Scholar
• Alving CR. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 20\(Suppl. 3), S56—S64 (2002).
   Google Scholar
• Descotes J, Ravel G, Ruat C. Vaccines: predicting the risk of allergy and autoimmunity. Toxicology 174 (1), 45–51 (2002).
   PubMed Web of Science ®Google Scholar
• Tam JR Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl Acad. Sci. USA 85 (15), 5409–5413 (1988).
   Google Scholar
• Le TP, Church LW, Corradin G et al Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants. Vaccine 16(2-3), 305–312 (1998).
   PubMed Web of Science ®Google Scholar
• Nardin EH, Oliveira GA, Calvo-Calle JM et al Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. j Infect. Dis. 182(5), 1486–1496 (2000).
   Google Scholar
• Edelman R. Vaccine adjuvants. Rev Infect. Dis. 2(3), 370–383 (1980).
   Google Scholar
• Goldenthal KL, Cavagnaro JA, Alving CR, Vogel FR. NCVDG Working Groups: safety evaluation of vaccine adjuvants: national co-operative vaccine development meeting working group. AIDS Res. Hum. Retroviruses 9, S47—S51 (1993).
   Web of Science ®Google Scholar
• Bussiere JL, McCormick GC, Green JD. Preclinical safety assessment considerations in vaccine development. In: Vaccine Design: the Subunit and Adjuvant Approach. Powell MF, Newman MJ (Eds.), Plenum Press, NY, USA 61–79 (1995).
   Google Scholar
• Davenport FM. Seventeen years' experience with mineral oil adjuvant influenza virus vaccines. Ann. Allergy 26(6), 288–292 (1968).
   PubMedGoogle Scholar
• Stuart-Harris CH. Adjuvant influenza vaccines. Bull. World Health Organ. 41(3), 617–621 (1969).
   PubMed Web of Science ®Google Scholar
• Chang JC, Diveley JP, Savary JR, Jensen PC. Adjuvant activity of incomplete Freund's adjuvant. Adv. Drug- Deily. Rev 32(3), 173–186 (1998).
   Google Scholar
• Beebe GW, Simon AH, Vivona S. Long-term mortality follow-up of army recruits who received adjuvant influenza virus vaccine in 1951–1953. Am. j Epidemiol. 95(4), 337–346 (1972).
   Google Scholar
• Schultz N, Oratz R, Chen D, Zeleniuch-Jacquotte A, Abeles G, Bystryn JC. Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine 13 (5), 503–508 (1995).
   PubMed Web of Science ®Google Scholar
• Keitel W, Couch R, Bond N, Adair S, Van Nest G, Dekker C. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccinell (9), 909–913 (1993).
   Google Scholar
• Cano CA. The multi-epitope polypeptide approach in HIV-1 vaccine development. Genet. Anal. 15(3–5), 149–153 (1999).
   Google Scholar
• Evans TG, McElrath MJ, Matthews T et al QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 19(15–16), 2080-2091 (2001).
   Google Scholar
• Gordon DM, Duffy PE, Heppner DG et al Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium fakiparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States. Am. .1. Trop. Med. Hyg. 55(1), 63–68 (1996).
   Google Scholar
• Rinn K, Schiffman K, Otero HO, Disis ML. Antigen-specific recall urticaria to a peptide-based vaccine. I Allergy Clin. Immunol. 104(1), 240–242 (1999).
   Web of Science ®Google Scholar
• Kashala O, Amador R, Valero MV et al. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine20(17–18), 2263–2277 (2002).
   Google Scholar
• Edelman R, Wasserman SS, Kublin JG etal. Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparumsporozoites. Vaccine 21(3–4), 269–280 (2002).
   Google Scholar
• Keefer MC, Wolff M, Gorse GJ et al Safety profile of Phase land II preventive HIV Type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retmrdruses13(14), 1163–1177 (1997).
   Google Scholar
• Beebe GW, Simon AH, Vivona S. Follow-up study on army personnel who received adjuvant influenza virus vaccine 1951–53. AinJ Med. Sci. 247,385-406 (1964).
   Google Scholar
• Page WF, Norman JE, Benenson AS. Long-term follow-up of army recruits immunized with Freund's incomplete adjuvanted vaccine. Vaccine Res. 2(3), 141–149 (1993).
   Google Scholar
• Jacobson RM, Adegbenro A, Pankratz VS, Poland GA. Adverse events and vaccination — the lack of power and predictability of infrequent events in pre-licensure study. Vaccine19(17-19), 2428–2433 (2001).
   PubMed Web of Science ®Google Scholar
• Waters RV, Terrell TG, Jones GH. Uveitis induction in the rabbit by muramyl dipeptides. Infect. Immun. 51(3), 816–825 (1986).
   Google Scholar
• Allison AC, Byars NE. Immunological adjuvants: desirable properties and side effects. Mal Immunol. 28(3), 279–284 (1991).
   Google Scholar
• McElrath MJ. Adjuvant effects on human immune responses in recipients of candidate HIV vaccines. IBC Conference: Novel Vaccine Strategies for NIucosal Immunisation Genetic Approaches and Adjuvants 24–26 (1994).
   Google Scholar
• Pearson CM. Experimental joint disease. Observations on adjuvant-induced arthritis. Chmn. as. 16,863–874 (1963).
   Google Scholar
• Kleinau S, Erlandsson H, Holmdahl R, KLareskog L. Adjuvant oils induce arthritis in the DA rat. I. Characterization of the disease and evidence for an immunological involvement. j Autoimmun. 4(6), 871–880 (1991).
   Google Scholar
• Murray R, Cohen P, Hardegree MC. Mineral oil adjuvants: biological and chemical studies. Ann. Allergy 30 (3), 146–151 (1972).
   Google Scholar
• Salk J, Salk D. Control of influenza and poliomyelitis with killed virus vaccines. Science 195(4281), 834–847 (1977).
   PubMed Web of Science ®Google Scholar
• Gherardi RIK, Coquet M, Cherin P et al Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 124(9), 1821–1831 (2001).
   PubMed Web of Science ®Google Scholar
• Goldenthal KL, Falk LA, Ball L, Geber A. Prelicensure evaluation of combination vaccines. Clin. Infect. Dis. 33\(Suppl. 4), S267—S273 (2001).
   Google Scholar
• Butler NR, Wilson BDR, Benson PF, Dudgeon JA, Ungar J, Beale AJ. Response of infants to pertussis vaccine at one week and to poliomyelitis, diphtheria and tetanus vaccine at six months. Lancet 2, 112–114 (1962).
   PubMed Web of Science ®Google Scholar
• Cvetanovic B, Uemura K. The present status of field and laboratory studies of typhoid and paratyphoid vaccines with special reference to studies sponsored by the World Health Organization. Bull. WHO 32,29–36 (1965).
   PubMed Web of Science ®Google Scholar
• Woolridge RL, Grayston JT, Chang IH, Yang CY, Cheng IKH. Long-term follow-up of the initial (1959–1960) trachoma vaccine field trial on Taiwan. Am j Ophthalmol 63(Suppl. 5), 1650–1655 (1967).
   Google Scholar
• Kasel JA, Couch RB, Douglas RG Jr. Antigenicity of alum and aqueous adenovirus hexon antigen vaccines in man. Immunol. 107(3), 916–919 (1971).
   Web of Science ®Google Scholar
• Davenport FM, Hennessy AV, Askin FB. Lack of adjuvant effect of A1PO4 on purified influenza virus hemagglutinins in man. J. hrimund 100(5), 1139–1140 (1968).
   Google Scholar
• Claesson BA, Trollfors B, Lagergard T et al Clinical and immunologic responses to the capsular polysaccharide of .thernophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children. j Pecliatr112 (5), 695–702 (1988).
   Google Scholar
• Vernier E Non-clinical vaccine safety assessment. Toxicology174(1), 37–43 (2002).
   Google Scholar
• O'Hagan DT, Jeffery H, Davis SS. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine11,965–969 (1993).
   PubMed Web of Science ®Google Scholar
• Gupta RK, Siber GR. Adjuvant properties of aluminum and calcium compounds. In: Vaccine Design: the Subunit and Adjuvant Approach. Powell MF, Newman MJ (Eds). Plenum Press, NY, USA 229–248 (1995).
   Google Scholar
• Baylor NW Egan W Richman P. Aluminum salts in vaccines — US perspective. Vaccine 20, S18—S23 (2002).
   Web of Science ®Google Scholar
• World Health Organization. Manual for the Production and Control of Vaccines — Tetanus Toxoid. BLGIUNDP/77.2nd Rev. 1st edn, BLGIUNDP/77 (1977).
   Google Scholar
• Majgaard Jensen O, Koch C. On the effect of Al(OH)3 as an immunological adjuvant. Acta Pathol MicrobioL Immun. Scand 96(3), 257–264 (1988).
   Google Scholar
• Bumford R. Aluminum salts: prospectives in their use as adjuvants. In: Immunological Adjuvants and Vaccines. Gregoriadis G, Allison AC, Poste G (Eds). Plenum Press, NY, USA 35–41 (1989).
   Google Scholar
• Stewart-Tull DE. Recommendations for the assessment of adjuvants (immunopotentiators). In: Immunological Adjuvants and Vaccines. Gregoriadis G, Allison AC, Poste G (Eds), Plenum Press, NY, USA, 213–226 (1989).
   Google Scholar
• Hardegree MC, Pittman M, Maloney CJ. Influence of mouse strain on the assayed potency (unitage) of tetanus toxoid. AppL Microbial. 24(1), 120–126 (1972).
   PubMedGoogle Scholar
• Matsuhasi T In: Proceedings of an Informal Consultation on the World Health Organization Requirements for Diphtheria, 7etanus, Pertussis and Combined Vaccines. Manclark CR (Ed.). Dept of Health and Human Services, United States Public Health Service, Bethesda, MD, USA, 55–58 (2001). DHHS Publication No. (FDA) 91–1174.
   Google Scholar
• Lyng J, Nyerges G. The second international standard for tetanus toxoid (adsorbed). j Biol. Stand. 12,121–130 (1984).
   PubMedGoogle Scholar
• Siber GR, Anderson R, Habafy M, Gupta RK. Development of a guinea-pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines. Vaccine 13(6), 525–531 (1995).
   PubMed Web of Science ®Google Scholar
• ICH. S6: Preclinical safety evaluation of biotechnology-derived pharmaceuticals. www.ifpma.org:pdfifpma:s6.pdf, (1997).
   Google Scholar
• Murphey-Corb M, Ohkawa S, Martin L, Wilson L, Bohm R, Blanchard J. In: Sixth Annual Meeting of the National Co-operative Vaccine Development Group for AIDS, Bethesda, MD (1993) (Abstract).
   Google Scholar
• Concept paper on the development of a Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on requirements for the evaluation of new adjuvants in vaccines. London: European Agency for the Evaluation of Medicinal Products, CPMP/BWP/6622/02 CPMP/BWP/6622/6602 (2002).
   Google Scholar
• ICH. S5a: Detection of toxicity to reproduction for medicinal products. www.ifpma.org/pdfifpma/s5a.pdf (1994).
   Google Scholar
• CPMP. Note for guidance on preclinical pharmacological and toxicological testing of vaccines CPMP/SWP/465/495 (1998).
   Google Scholar
• US Food and Drug Administration. Guidance for industry: Considerations for reproductive toxicity studies for preventive vaccines for infectious disease indications (2002). www.fda.govicberigdlnsireprotox.pdf.
   Google Scholar
• Relyveld EH. Preparation and use of calcium phosphate adsorbed vaccines. Dev. Biol. Stand. 65,131–136 (1986).
   PubMedGoogle Scholar
• Gupta RK. Aluminum compounds as vaccine adjuvants. Adv. Drug- Deliv. Rev 32(3), 155–172 (1998).
   Google Scholar
• Blennow M, Granstrom M, Olin P etal. Preliminary data from a clinical trial (Phase 2) of an acellular pertussis vaccine, J-NTH-6. Dev. Biol. Stand. 65,185-190 (1986).
   Google Scholar
• Mark A, Bjorksten B, Granstrom M. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines. Vaccine 13(7), 669–673 (1995).
   PubMed Web of Science ®Google Scholar
• Ratliff DA, Bums-Cox CJ. Anaphylaxis to tetanus toxoid. BE Med. 288,144 (1984).
   PubMedGoogle Scholar
• Schirmbeck R, Melber K, Kuhrober A, Janowicz ZA, Reimann J. Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T-lymphocyte responses in vivo. j Immunol 152 (3), 1110–1119 (1994).
   Google Scholar
• Sanchez-Pescador L, Burke RL, Ott G, Van Nest G. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. j Immunol 141(5), 1720–1727 (1988).
   PubMed Web of Science ®Google Scholar
• Ott G, Barchfeld GL, Chemoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol 6,277–296 (1995).
   Google Scholar
• Minutello M, Senatore F, Cecchinelli G et al Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17, 99–104 (1999).
   PubMed Web of Science ®Google Scholar
• Heineman TC, Clements-Mann ML, Poland GA et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17(22), 2769–2778. (1999).
   Google Scholar
• Baldo V, Menegon T, Bonello C, Floreani A, Trivello R. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 19(25-26), 3472–3475 (2001).
   PubMed Web of Science ®Google Scholar
• Holzer BR, Hatz C, Schmidt-Sissolak D, Gluck R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 14, 982–986 (1996).
   PubMed Web of Science ®Google Scholar
• Gluck U, Gebbers JO, Gluck R, Althaus B, Egger M. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. j ViroL 73,7780–7786 (1999).
   Google Scholar
• Ryan ET, Calderwood SB. Cholera vaccines. Clin. Infect. Dis. 31,561–565 (2000).
   PubMedGoogle Scholar
• Clemens JD, Sack DA, Harris JR et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 2 (8499), 124–127 (1986).
   PubMed Web of Science ®Google Scholar
• van Loon FP, Clemens JD, Chakraborty J et al. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 14(2), 162–166 (1996).
   Google Scholar
• Clemens JD, Sack DA, Harris JR etal. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia col1 results of a large-scale field trial. j Infect. Dis. 158(2), 372–377 (1988).
   Google Scholar
• Lesourd BM, Vincent-Falquet JC, Deslandes D, Musset M, Moulias R Influenza vaccination in the elderly: improved antibody response with Imuthiol (Na diethyldithiocarbamate) adjuvant therapy. Int. knmunophatmacol 10(2), 135–143 (1988).
   PubMed Web of Science ®Google Scholar
• Gravenstein S, Duthie EH, Miller BA etal. Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study.j Am Ceriatc Sx. 37(1), 1–8 (1989).
   Google Scholar
• Goodman MG. A new approach to vaccine adjuvants. Immunopotentiation by intracellular T-helper-like signals transmitted by loxoribine. Phatm. Biotechnol 6,581–609 (1995).
   Google Scholar
• Lin R, Tarr PE, Jones TC. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Gun. Infect. Dis. 21(6), 1439–1449 (1995).
   Google Scholar
• Haigwood NL, Nara PL, Brooks E et al. Native but not denatured recombinant human immunodeficiency virus Type 1 gp120 generates broad spectrum neutralizing antibodies in baboons. J. Vim!. 66(1), 172–182 (1992).
   Google Scholar
• Freund J, Casals J, Page-Hosmer E. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc. Soc. Exp. Biol. Med. 37, 509–513 (1937).
   Google Scholar
• Le Moignic, Pinoy. Les vaccins en emulsion dans les corps gras ou 'lipovaccins'. Comptes Rendus de la societe de Biologie 79,201–203 (1916).
   Google Scholar
• Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 19(17-19), 2666–2672 (2001).
   PubMed Web of Science ®Google Scholar
• Allison AC. Squalene and squalane emulsions as adjuvants. Methods 19(1), 87–93 (1999).
   PubMed Web of Science ®Google Scholar
• Bollinger JN. Metabolic fate of mineral oil adjuvants using 14C-labeled tracers I: mineral oil. j Phatm. Sci 59,1084–1088 (1970).
   Google Scholar
• van Driel WJ, Ressing ME, Kenter GG et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a Phase I—II trial. Eur Cancer 35 (6), 946–952 (1999).
   Google Scholar
• Slingluff CL Jr, Yamshchikov G, Neese P et al Phase I trial of a melanoma vaccine with gp100(280–288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Gun. Cancer Res. 7(10), 3012–3024 (2001).
   Google Scholar
• Lawrence GVV, Saul A, Giddy AJ, Kemp R, Pye D. Phase I trial in humans of an oil-based adjuvant SEPPIC Montanide ISA 720. Vaccine 15(2), 176–178 (1997).
   Google Scholar
• Genton B, Al-Yaman F, Anders R et al Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 18(23), 2504–2511 (2000).
   PubMed Web of Science ®Google Scholar
• Lopez JA, Weilenman C, Audran R et al A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T-lymphocyte immune response in humans. Implications for vaccination strategies. Eurj Immunol 31(7), 1989-1998 (2001).
   Google Scholar
• Toledo H, Baly A, Castro 0 etal. A Phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 19(30), 4328–4336 (2001).
   Google Scholar
• Saul A, Lawrence G, Smillie A et al Human Phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide I5A720 adjuvant. Vaccine 17(23–24), 3145–3159 (1999).
   Google Scholar
• Lawrence G, Cheng QQ, Reed C et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 18(18), 1925-1931 (2000).
   Google Scholar
• White RG, Jolles P, Samour D, Lederer E. Correlation of adjuvant activity and chemical structure of wax D fractions of mycobacteria. Immunology 7, 158–163 (1964).
   PubMed Web of Science ®Google Scholar
• Telzak E, Wolff SM, Dinarello CA et al Clinical evaluation of the immunoadjuvant murabutide, a derivative of MDP, administered with a tetanus toxoid vaccine. Infect. Dis. 153(3), 628–633 (1986).
   Web of Science ®Google Scholar
• Chedid LA, Parant MA, Audibert FM et al Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect. Immun. 35 (2), 417–424 (1982).
   PubMed Web of Science ®Google Scholar
• Byars NE, Allison AC, Harmon MW Kendal AP Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation. Vaccine 8(1), 49–56 (1990).
   PubMed Web of Science ®Google Scholar
• Audibert F, Parant M, Damais C et al. Dissociation of immunostimulant activities of muramyl dipeptide (MDP) by linkingamino-acids or peptides to the glutaminyl residue. Biochem. Biophys. Res. Commun. 96(2), 915–923 (1980).
   Google Scholar
• Tamura M, Yoo YC, Yoshimatsu K et al Effects of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen. Vaccine 13(1), 77–82 (1995).
   PubMed Web of Science ®Google Scholar
• Byars NE, Nakano G, Welch M, Lehman D, Allison AC. Improvement of hepatitis B vaccine by the use of a new adjuvant. Vaccine 9(5), 309–318 (1991).
   PubMed Web of Science ®Google Scholar
• Ewasyshyn M, Caplan B, Bonneau AM et al Comparative analysis of the immunostimulatory properties of different adjuvants on the immunogenicity of a prototype parainfluenza virus Type 3 subunit vaccine. Vaccine 10(0,412–420 (1992).
   Google Scholar
• Byars NE, Fraser-Smith EB, Pecyk RA et al Vaccinating guinea-pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. Vaccine 12(3), 200–209 (1994).
   PubMed Web of Science ®Google Scholar
• Morgan AJ, Allison AC, Finerty S, Scullion FT, Byars NE, Epstein MA. Validation of a first-generation Epstein—Barr virus vaccine preparation suitable for human use. j Merl Viral 29(1), 74–78 (1989).
   PubMed Web of Science ®Google Scholar
• Murphey-Corb M, Martin LN, Davison-Fairburn B et al A formalin-inactivated whole SW vaccine confers protection in macaques. Science 246(4935), 1293–1297 (1989).
   PubMed Web of Science ®Google Scholar
• Byars NE, Nakano G, Welch M, Allison AC. Use of Syntex adjuvant formulation to enhance immune responses to viral antigens. In: Vaccines. Gregoriadis G, Allison AC, Poste G (Eds). Plenum Press, NY, USA, 33–42 (1991).
   Google Scholar
• Girard M, Kieny MP, Pinter A et al Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl Acad. Sci. USA 88(2), 542–546 (1991).
   Google Scholar
• Stieneker F, Kersten G, van Bloois L et al Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. Vaccine 13 (1), 45–53 (1995).
   Google Scholar
• Stoute JA, Slaoui M, Heppner DG et al A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Rasmodium falcipamm malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. Med 336(2), 86–91. (1997).
   Google Scholar
• Bojang KA, Milligan PJ, Pinder M et al Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358(9297), 1927-1934 (2001).
   Google Scholar
• Gerard CM, Baudson N, Kraemer K et al Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 19(17-19), 2583–2589 (2001).
   PubMed Web of Science ®Google Scholar
• Desombere I, Van der Wielen M, Van Damme P et al. Immune response of HLA DQ2 positive subjects, vaccinated with HBsAWAS04, a hepatitis B vaccine with a novel adjuvant. Vaccine 20, 2597–2602 (2002).
   Google Scholar
• McCormack S, Tilzey A, Carmichael A etal. A Phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine 18(13), 1166–1177 (2000).
   Google Scholar
• Johnson AG, Gaines S, Landy M. Studies on the 0 antigen of Salmonella Ophosa V. Enhancement of antibody responose to protein antigens by the purified lipopolysaccharide. I Exp. Med. 103, 225–246 (1956).
   Google Scholar
• Luderitz 0, Galanos C, Rietschel ET Endotoxins of Gram-negative bacteria. Pharmacol Ther. 15(3), 383–402 (1981).
   Google Scholar
• Ribi E, Amano K, Cantrell JL, Schwartzman S, Parker R, Takayama K. Preparation and antitumor activity of nontoxic lipid A. Cancer Immunol Immunother. 12,91–96 (1982).
   Web of Science ®Google Scholar
• Qureshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella Ophimurium. .1. Biol. Chem. 257(19), 11808–11815 (1982).
   Google Scholar
• Myers KR, Truchot AT, Ward JR, Hudson Y, Ulrich JT. A critical determinant of lipid A endotoxic activity. In: Celiular and Molecular Aspects of Endotoxin Reactions. Nowotny A, Spitzer JJ, Ziegler EJ (Eds). Elsevier, Amsterdam, The Netherlands 145–156 (1996).
   Google Scholar
• Baldridge JR, Crane RT. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 19(1), 103–107 (1999).
   PubMed Web of Science ®Google Scholar
• Schneerson R, Fattom A, Szu SC et al. Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide—protein conjugates by concurrent injection with MPL. Immunol 147(7), 2136–2140 (1991).
   Web of Science ®Google Scholar
• Garg M, Subbarao B. Immune responses of systemic and mucosal lymphoid organs to Pnu-Imune vaccine as a function of age and the efficacy of monophosphoryl lipid A as an adjuvant. Infect. 'minim. 60(6), 2329–2336 (1992).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Moreux E, Verhasselt B, Biemaux S, Brulein V, Francotte M. In: 33ml Intemcience Confemnce on Antimicrobial Agents and Chemotherapy 341 (1993) (Abstract).
   Google Scholar
• Zhou F, Huang L. Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes. Vaccinell(11), 1139–1144 (1993).
   PubMed Web of Science ®Google Scholar
• Dijkstra J, Mellors JW, Ryan JL, Szoka PC. Modulation of the biological activity of bacterial endotoxin by incorporation into liposomes. j Immunol 138(8), 2663–2670 (1987).
   PubMed Web of Science ®Google Scholar
• Carozzi S, Salit M, Cantaluppi A et al. Effect of monophosphoryl lipid A on the in vitro function of peritoneal leukocytes from uremic patients on continuous ambulatory peritoneal dialysis. j Clin. Nlicrobiol 27(8), 1748–1753 (1989).
   Web of Science ®Google Scholar
• Ribi E, Cantrell JL, Takayama K, Ribi HO, Myers KR, Qureshi N. Modulation of humoral and cell-mediated immune responses by a structurally established nontoxic lipid A. hnmunobiology and hnmunopharmacology of Bacterial Endotoxins. Szentivanyi A, Friedman H (Eds). Plenum Press, NY, USA, 407–420 (1986).
   Google Scholar
• Baker PJ, Haslov KR, Fauntleroy MB, Stashak PW, Myers K, Ulrich JT. Enrichment of suppressor T-cells by means of binding to monophosphoryl lipid A. Infect. Immun. 58(3), 726–731 (1990).
   PubMed Web of Science ®Google Scholar
• Domer JE, Human LG, Andersen GB, Rudbach JA, Asherson GL. Abrogation of suppression of delayed hypersensitivity induced by Candidagbicans-derived mannan by treatment with monophosphoryl lipid A. Infect. hnmun. 61(5) (1993).
   Google Scholar
• Gustafson GL, Rhodes MJ. Bacterial cell wall products as adjuvants: early interferon y as a marker for adjuvants that enhance protective immunity. Res. Immunol 143(5), 483–488 (1992).
   PubMedGoogle Scholar
• Vemacchio L, Bernstein H, Pelton S et al Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM(197) conjugate vaccine in healthy toddlers. Vaccine 20(31–34 3658–3667 (2002).
   Google Scholar
• Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W Shau HY, Lind S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 48(20), 5883–5893 (1988).
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Harel W Kempf RA et al Active-specific immunotherapy for melanoma. j Clin. Oncol 8(5), 856–869 (1990).
   Google Scholar
• Elliott GT, McLeod RA, Perez J, Von Eschen KB. Interim results of a Phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin. Surg. Oncol 9(3), 264–272 (1993).
   Google Scholar
• MacLean GD, Bowen-Yacyshyn MB, Samuel J et al Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen—Friedenreich) determinant using a synthetic carbohydrate antigen. Immunother. 11(4), 292–305 (1992).
   Google Scholar
• MacLean GD, Reddish M, Koganty RR et al Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer hnmunol. Immunother 36(4), 215–222 (1993).
   Web of Science ®Google Scholar
• Rickman LS, Gordon DM, Wistar R Jr et al Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A and squalane in malaria circumsporozoite protein vaccine. Lancet337 (87 48), 998–1001 (1991).
   Google Scholar
• Van Damme P, Thoelen S, Van Passchen M, Leroux-Roels G, Meeus A, Slaoui M. In: 33ml Interscience Conference on Antimicrobial Agents and Chemotherapy 241 (1993) (Abstract).
   Google Scholar
• Thoelen S, Van Damme P, Meeus A, Collar G, Slaoui M, Vandepapeliere P In: 33m1 Interscience Conference on Antimicrobial Agents and Chemotherapy 182 (1993) (Abstract).
   Google Scholar
• Gordon DM, McGovern TW, Krzych U et al Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. Infect. Dis. 171(6), 1576–1585 (1995).
   Web of Science ®Google Scholar
• Leroux-Rods G, Moreau E, Desombere I, Crayne 0, Francotte M, Pala P In: 34th Interscience Conference on Antimicrobial Agents and Chemotherapy 205 (1994) (Abstract).
   Google Scholar
• Koutsoukos M, Lerous G, Vandepapeliere P, Slaoui M, Pala P. In: 34th Interscience Confemnce on Antimicrobial Agents and Chemotherapy 217 (1994) (Abstract).
   Google Scholar
• Thoelen S, Van Damme P, Mathei C et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16 (7), 708–714 (1998).
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Wheeler AW, Stuebner P, Horak E A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56(6), 498–505 (2001).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6(12), 1403–1406 (2000).
   PubMed Web of Science ®Google Scholar
• Gaerefia-Burgueflo F, Hall ER, Taylor DN et al Safety and immunogenicity of a prototype enterotoxigenic Escherichia cob vaccine administered transcutaneously. Infect. Immun. 70(4), 1874–1880 (2002).
   PubMed Web of Science ®Google Scholar
• Barackman JD, Ott G, Pine S, O'Hagan DT Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional im. immunization. Gun. Diagn. Lab. Immunal 8(3), 652–657 (2001).
   Google Scholar
• Ryan EJ, McNeela E, Murphy GA et al Mutants of Escherichia coil heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Thl and Th2 cells. Infect. Immun. 67(12), 6270–6280 (1999).
   Google Scholar
• Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 69(6), 3581–3590 (2001).
   PubMed Web of Science ®Google Scholar
• Campbell JB, Peerbaye YA. Saponin. Res. Immunal 143(5), 526–530, discussion 577–578 (1992).
   Google Scholar
• Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. Immunal 146(2), 431–437 (1991).
   PubMed Web of Science ®Google Scholar
• Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308(5958), 457–460 (1984).
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Osterhaus A. A novel generation of viral vaccines based on the ISCOM matrix. In: Vaccine Design: the Subunit and Adjuvant Approach. Powell ME, Newman MJ (Eds). Plenum Press, USA, 543–558 (1995).
   Google Scholar
• Sundquist B, Lovgren K, Morein B. Influenza virus ISCOMs: antibody response in animals. Vaccine6(1), 49–53 (1988).
   PubMed Web of Science ®Google Scholar
• Lovgren K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand. j Immunal 27(2), 241–245 (1988).
   PubMed Web of Science ®Google Scholar
• Jones PD, Tha Ella R, Morein B, Lovgren K, Ada GL. Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatory complexes (iscoms). Scand. j Imurunol. 27(6), 645–652 (1988).
   PubMed Web of Science ®Google Scholar
• Thapar MA, Parr EL, Bozzola JJ, Parr MB. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM). Vaccine 9(2), 129–133 (1991).
   PubMed Web of Science ®Google Scholar
• Villacres-Eriksson M. Induction of immune responses by ISCOMS. Swedish University of Agricultural Sciences, Uppsala, Sweden (1993).
   Google Scholar
• özel Hoglund, M. S, Gelderblom Gelderblom H, Morein B. Quaternary structure of the immunostimulating complex (ISCOM). Ultmstruct. Mal Struct. Res. 102 (3), 240–248 (1989).
   Google Scholar
• Rönnberg B, Felcadu M, Morein B. Adjuvant activity of non-toxic Quillaja saponada Molina components for use in ISCOM matrix. Vaccine 13(14), 1375–1382 (1995).
   PubMed Web of Science ®Google Scholar
• Ennis FA, Cruz J, Jameson J, Klein M, Burt D, Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T-lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology259(2), 256–261 (1999).
   PubMed Web of Science ®Google Scholar
• Newman MJ, Wu JY, Coughlin RT et al. Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates. AIDS Res. Hum. Retroviruses 8(8), 1413–1418 (1992).
   Google Scholar
• Marciani DJ, Kensil CR, Beltz GA, Hung CH, Cronier J, Aubert A. Genetically-engineered subunit vaccine against feline leukemia virus: protective immune response in cats. Vaccine 9(2), 89–96 (1991).
   PubMed Web of Science ®Google Scholar
• Ma J, Bulger PA, Davis DR et al. Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Bormlia burgdorferi Vaccine 12(10), 925–932 (1994).
   Google Scholar
• Ma J, Bulger PA, Dante S, Davis DR, Perilli-Palmer B, Coughlin RT. Characterization of canine humoral immune responses to outer surface protein subunit vaccines and to natural infection by Lyme disease spirochetes. j Infect. Dis. 171(4), 909–915 (1995).
   Google Scholar
• Coughlin RT, Fish D, Mather TN, Ma J, Pavia C, Bulger P Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB and the saponin adjuvant Q521. j Infect. Dis. 171(4), 1049–1052 (1995).
   Google Scholar
• Newman MJ, Munroe KJ, Anderson CA et al Induction of antigen-specific killer T-lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant. AIDS Rej. Hum. Retmviruses10(7), 853–861 (1994).
   Google Scholar
• Wu JY, Gardner BH, Murphy CI et al. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J. Imurunol. 148(5), 1519–1525 (1992).
   Google Scholar
• Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA. Helper-cytotoxic T-lymphocyte (CTL) determinant linkage required for priming of antiHIV CD8+ CTL in vivo with peptide vaccine constructs. J. Imurunol. 152 (2), 543–556 (1994).
   Google Scholar
• Powell MF, Cleland JL, Eastman DJ et al. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 Q521 vaccine in baboons. AIDS Res. Hum. Retroviruses 10\(Suppl. 2), S105—S108 (1994).
   Google Scholar
• Powell MF, Eastman DJ, Lim A et al Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea-pigs. AIDS Res. Hum. Retrovirusesll (2), 203–209 (1995).
   Google Scholar
• Coughlin RT, Fattom A, Chu C, White AC, Winston S. Adjuvant activity of QS-21 for experimental E. coil 018 polysaccharide vaccines. Vaccine 13 (1), 17–21 (1995).
   Google Scholar
• Van Dam G, Verheul AF, Zigterman G, De Reuver M, Snippe H. Nonionic blocked polymer surfactants enhance the avidity of antibodies in polyclonal antisera against Streptococcus pneumoniae Type 3 in normal and Xid mice. Immunol. 143,3049-3053 (1989).
   Google Scholar
• Zigterman GJ, Schotanus K, Ernste EB et al Nonionic block polymer surfactants modulate the humoral immune response against Streptococcus pneumoniae-derived hexasaccharide-protein conjugates. Infect. Immun. 57(9), 2712–2718 (1989).
   PubMed Web of Science ®Google Scholar
• Baker PJ, Fauntleroy MB, Stashak PW, Hiernaux JR, Cantrell JL, Rudbach JA. Adjuvant effects of trehalose dimycolate on the antibody response to Type III pneumococcal polysaccharide. Infect. Immun. 57(3), 912–917 (1989).
   PubMed Web of Science ®Google Scholar
• Fattom A, Li X, Cho YH et al. Effect of conjugation methodology, carrier protein and adjuvants on the immune response to Staphylococcusaureurcapsular polysaccharides. Vaccine 13(14), 1288–1293 (1995).
   PubMed Web of Science ®Google Scholar
• Kensil CR, Barrett C, Kushner N et al. Development of a genetically engineered vaccine against feline leukemia virus infection. A/17. Vet. Merl Assoc. 199(10), 1423–1427 (1991).
   Google Scholar
• Livingston PO, Adluri S, Helling F et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12(14), 1275–1280 (1994).
   Google Scholar
• Brey RN. Development of vaccines based on formulations containing nonionic block polymers. In: Vaccine Design: the Subunit ancl Adjuvant Approach. Powell ME, Newman MJ (Eds). Plenum Press, New York, NY, USA, 297–312 (1995).
   Google Scholar
• Byars NE, Allison AC. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. Vaccine 5(3), 223–228 (1987).
   PubMed Web of Science ®Google Scholar
• Hunter R, Strickland F, Kezdy E The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile—lipophile balance. J. Immunol 127(3), 1244–1250 (1981).
   Google Scholar
• Hunter RL, Bennett B. The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock co-polymers. J. Immunol 133(6), 3167–3175 (1984).
   Google Scholar
• Howerton DA, Hunter RL, Ziegler HK, Check IJ. Induction of macrophage Ia expression in vivo by a synthetic block co-polymer, L81. J. Immunol 144(5), 1578–1584 (1990).
   Google Scholar
• Bennett B, Check IJ, Olsen MR, Hunter RL. A comparison of commercially available adjuvants for use in research. J. humunol Methods 153(1-2), 31–40 (1992).
   PubMed Web of Science ®Google Scholar
• Newman MJ, Actor JK, Balusubramanian M, Jagannath C. Use of nonionic block co-polymers in vaccines and therapeutics. Grit. Rev. Ther. Drug. Carrier Syst. 15 (2), 89–142 (1998).
   Google Scholar
• Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. j immund 163(8), 4481–4488 (1999).
   Google Scholar
• Lachman LB, Shih L-CN, Rao XM, Ullrich SE, Cleland JL. Cytokine-containing liposomes as adjuvants for subunit vaccines. In: Vaccine Design: the Subunit and Adjuvant Approach. Powell ME, Newman MJ (Eds). Plenum Press, NY, USA 659–672 (1995).
   Google Scholar
• Tao MH, Levy R Idiotypeigranulocyte—macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Natum362(6422), 755–758 (1993).
   PubMed Web of Science ®Google Scholar
• Murray PJ, Aldovini A, Young RA. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette—Guerin strains that secrete cytokines. Proc. Nat! Acad. Sci. USA 93(2), 934–939 (1996).
   Google Scholar
• Hughes HP, Babiuk LA. The adjuvant potential of cytokines. Biotechnol Ther. 3(3-4), 101–117 (1992).
   Google Scholar
• Health AW, Playfair JHL. Cytokines as immunological adjuvants. Biotechnol Ther 3,427–434 (1993).
   Google Scholar
• Tagliabue A, Boraschi D. Cytokines as vaccine adjuvants: interleukin-1 and its synthetic peptide 163–171. Vaccine 11(5), 594–595 (1993).
   Google Scholar
• Dong P, Brunn C, Ho RJY. Cytokines as vaccine adjuvants: Current status and potential applications. In: Vaccine Design: The Subunit and Adjuvant Approach. Powell ME, Newman MJ (Eds.), Plenum Press, NY, USA, 625–644 (1995).
   Google Scholar
• Heath AW Cytokines as immunological adjuvants. In: Vaccine Design: the Subunit anc Adjuvant Approach. Powell ME, Newman MJ (Eds). Plenum Press, New York, USA 645–658 (1995).
   Google Scholar
• OHagan DT, MacKichan ML, Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng. 18(3), 69–85 (2001).
   PubMedGoogle Scholar
• Warren TL, Weiner GJ. Uses of granulocyte—macrophage colony-stimulating factor in vaccine development. CUM Opin. Hernatol 7(3), 168–173 (2000).
   Google Scholar
• Schijns VE. Induction and direction of immune responses by vaccine adjuvants. Grit. Rev Immunol 21(1-3), 75–85 (2001).
   PubMed Web of Science ®Google Scholar
• Grob PJ, Joller-Jemelka HI, Binswanger U, Zaruba K, Descoeudres C, Fernex M. Interferon as an adjuvant for hepatitis B vaccination in non- and low-responder populations. Eur j Clin. IVlicrobiol. 3(3), 195–198 (1984).
   Google Scholar
• Quiroga JA, Castillo I, Porres JC et al Recombinant y-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology12 (4 Pt 1), 661–663 (1990).
   Google Scholar
• Patou G, Scott GM, Kelsey MC, Playfair JHL. Gamma interferon as an adjuvant to hepatitis B vaccine. J. Interferon Res. 9, S261 Abstract (1989).
   Google Scholar
• Meuer SC, Dumann H, Meyer zum Buschenfelde IKH, Kohler H. Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet1(8628), 15–18 (1989).
   Google Scholar
• Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 344(8926), 856–857 (1994).
   Google Scholar
• Sturchler D, Berger R, Etlinger H et al. Effects of interferons on immune response to a synthetic peptide malaria sporozoite vaccine in non-immune adults. Vaccine 7(5), 457–461 (1989).
   PubMed Web of Science ®Google Scholar
• Sturchler D, Zimmer G, Berger R et al Interferon-a and synthetic peptide malaria sporozoite vaccine in non-immune adults: antibody response after 40 weeks. Buff. 14brIcl Health Chgan. 68 (Suppl.) 38–41 (1990).
   Google Scholar
• Scott P. IL-12: initiation cytokine for cell-mediated immunity. Science 260(5107), 496–497 (1993).
   Google Scholar
• Manetti R, Gerosa F, Giudizi MG et al Interleukin-12 induces stable priming for interferon y (IFN-y) production during differentiation of human T-helper (Th) cells and transient IFN-y production in established Th2 cell clones. I Exp. Med. 179(4), 1273–1283 (1994).
   Google Scholar
• Araneo BA, Woods ML 2nd, Daynes RA. Reversal of the immunosenescent phenotype by dehydroepiandrosterone: hormone treatment provides an adjuvant effect on the immunization of aged mice with recombinant hepatitis B surface antigen. j Infect. Dis. 167(4), 830–840 (1993).
   Google Scholar
• Danenberg HD, Ben-Yehuda A, Zakay-Rones Z, Friedman G. Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. Vaccine 13 (15), 1445–1448 (1995).
   PubMed Web of Science ®Google Scholar
• Danenberg HD, Ben-Yehuda A, Zakay-Rones Z, Gross DJ, Friedman G. Dehydroepiandrosterone treatment is not beneficial to the immune response to influenza in elderly subjects. j Gun. Endocrinol. 114tab. 82(9), 2911–2914 (1997).
   Google Scholar
• Evans TG, Schiff M, Graves B et al The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Gun. Nephrol. 54(2), 138–142 (2000).
   Web of Science ®Google Scholar
• Heath AW, Playfair JH. Cytokines as immunological adjuvants. Vaccine 10(7), 427–434 (1992).
   PubMed Web of Science ®Google Scholar
• Valensi JP, Carlson JR, Van Nest GA. Systemic cytokine profiles in BALM mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. j Immunol 153(9), 4029–4039 (1994).
   Google Scholar
• Krieg AM, Yi AK, Matson S et al CpG motifs in bacterial DNA trigger direct B -cell activation. Nature 374 (6522), 546–549 (1995).
   PubMed Web of Science ®Google Scholar
• Davis HL, Suparto, II, Weeratna RR et al CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18(18), 1920–1924 (2000).
   PubMed Web of Science ®Google Scholar
• Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM. CpG oligodeoxynucleotides as vaccine adjuvants in primates. I Immunol. 168(4), 1659–1663 (2002).
   Google Scholar
• Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. Immund. 166(4), 2372–2377 (2001).
   PubMed Web of Science ®Google Scholar
• Krieg AM. From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. Antisense Nucleic Acid Drug. Dev. 11 (3), 181–188 (2001).
   Web of Science ®Google Scholar
• Agrawal S, Kandimalla ER. Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med. 8(3), 114–121 (2002).
   Google Scholar
• Davis HL, Cooper CL, Morris ML, Elfer SM, Cameron DW, Heathcote J. In: 3m1 Annual Confemnce on Vaccine Reseamh. Washington, DC, USA (2000) (Abstract #S25).
   Google Scholar
• Halperin SA, Van Nest G, Halperin B et al In: 41st Annual ICAAC Chicago, IL, USA (2001) (Abstract #1578).
   Google Scholar
• Pye D, Vandenberg KL, Dyer SL et al Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. Vaccine 15(9), 1017–1023 (1997).
   Google Scholar
• Ivins BE, Welkos SL, Little SF, Crumrine MET, Nelson GO. Immunization against anthrax with Bacilius anthracis protective antigen combined with adjuvants. Infect. Immun. 60(2), 662–668 (1992).
   Google Scholar
• Wang R, Charoenvit Y, Corradin G et al Induction of protective polyclonal antibodies by immunization with a Rasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. Immunol 154(6), 2784–2793 (1995).
   Web of Science ®Google Scholar
• Protection of macaques against simian immunodeficiency virus infection with inactivated vaccines: comparison of adjuvants, doses and challenge viruses. The European Concerted Action on 'Macaque Models for AIDS Research'. Vaccine 13(3), 295–300 (1995).
   PubMedGoogle Scholar
• Lofthouse SA, Andrews AE, Nash AD, Bowles VM. Humoral and cellular responses induced by intradermally administered cytokine and conventional adjuvants. Vaccine 13(12), 1131–1137 (1995).
   PubMed Web of Science ®Google Scholar
• Kester KE, McKinney DA, Tomieporth N et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falcipatvm malaria.j Infect. Dis. 183 (4), 640–647 (2001).
   Google Scholar
• Lalvani A, Moris P, Voss G et al Potent induction of focused Thl-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falcipatvm malaria vaccine. J. Infect. Dis. 180(5), 1656–1664 (1999).
   Google Scholar
• Stoute JA, Kester KE, Krzych U et al Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. j Infect. Dis. 178(4), 1139–1144 (1998).
   Google Scholar
• Doherty JF, Pinder M, Tornieporth N et al A Phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. Am. j Tmp. Med. Hyg. 61(6), 865–868 (1999).
   Google Scholar
• Clinical Trial of Advanced Malaria Vaccine Candidate Begins in Mozambique. Malaria Vaccine Initiative, CISM and Hospital Clinic of the University of Barcelona (2002). http://www.malariavaccine.org/files/ 200206-Mozambique.htm.
   Google Scholar